Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 265 followers
Latest posts
Last updated about 21 hours ago
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
about 21 hours ago
Primary overall survival analysis from the Phase 3 monarchE study of Verzenio...
WHO Foundation and Lilly Collaborate to Support Global Dementia Action Plan
about 23 hours ago
Berlin, October 13, 2025 -- The WHO Foundation and Lilly have announced...
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
7 days ago
Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical...
Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem
18 days ago
New 82,514 square foot facility will accommodate up to 15 biotech companies...
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
18 days ago
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive...
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
19 days ago
An estimated 50% of patients with ER+, HER2 – metastatic breast cancer...
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
21 days ago
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020...
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
26 days ago
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at...
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
27 days ago
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with...
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
27 days ago
The investigational once-daily oral pill led to an average weight loss of...
Lilly announces plans to build $5 billion manufacturing facility in Virginia
28 days ago
New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API)...
Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
about 1 month ago
INDIANAPOLIS , Sept. 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...